Navigation Links
Synthetic HDL: A new weapon to fight cholesterol problems

EVANSTON, Ill. --- Buttery Christmas cookies, eggnog, juicy beef roast, rich gravy and creamy New York-style cheesecake. Happy holiday food unfortunately can send blood cholesterol levels sky high.

Northwestern University scientists now offer a promising new weapon -- synthetic high-density lipoprotein (HDL), the "good" cholesterol -- that could help fight chronically high cholesterol levels and the deadly heart disease that often results.

The researchers successfully designed synthetic HDL and show that their nanoparticle version is capable of irreversibly binding cholesterol. The synthetic HDL, based on gold nanoparticles, is similar in size to HDL and mimics HDL's general surface composition.

The study is published online by the Journal of the American Chemical Society (JACS).

"We have designed and built a cholesterol sponge. The synthetic HDL features the basics of what a great cholesterol drug should be," said Chad A. Mirkin, George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences, professor of medicine and professor of materials science and engineering. Mirkin and Shad Thaxton, M.D., assistant professor of urology in Northwestern's Feinberg School of Medicine, led the study.

"Drugs that lower the bad cholesterol, LDL, are available, and you can lower LDL through your diet, but it is difficult to raise the good cholesterol, HDL," said Mirkin. "I've taken niacin to try and raise my HDL, but the side effects are bad so I stopped. We are hopeful that our synthetic HDL will one day help fill this gap in useful therapeutics."

In creating synthetic HDL the researchers started with a gold nanoparticle as the core. They then layered on a lipid that attaches to the gold surface, then another lipid and last a protein, called APOA1, the main protein component of naturally occurring HDL. The final high-density lipoprotein nanoparticles are each about 18 nanometers in diameter, a size similar to natural HDL.

"Cholesterol is essential to our cells, but chronic excess can lead to dangerous plaque formation in our arteries," said Thaxton. "HDL transports cholesterol to the liver, which protects against atherosclerosis. Our hope is that, with further development, our synthetic form of HDL could be used to increase HDL levels and promote better health."

"HDL is a natural nanoparticle, and we've successfully mimicked it," said Mirkin, director of Northwestern's International Institute for Nanotechnology. "Gold is an ideal scaffolding material -- it's size and shape can be tailored, and it can be easily functionalized. Using gold nanoparticles, which are non-toxic, for synthetic HDL bodes well for the development of a new therapeutic."

The development of synthetic HDL is a result of a successful collaboration between scientists in Northwestern's department of chemistry and the Feinberg School. Bringing these two groups together, says Mirkin, should lead to major advances in translational research. Their next step is to further study the synthetic HDL in biologically relevant conditions and measure and evaluate the cholesterol-binding properties.


Contact: Marla Paul
Northwestern University

Related medicine news :

1. New center launched today to spearhead UK research in synthetic biology
2. Researcher refining synthetic molecules to prevent HIV resistance
3. FDA Approves Durameds Synthetic Conjugated Estrogens-A Vaginal Cream
4. Caltech engineers build first-ever multi-input plug-and-play synthetic RNA device
5. Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications
6. Pioneering Solutions To Fight Staph, MRSA Infections in Sports Facilities and Synthetic Turf Fields
7. Safety of Synthetic Turf Validated by NJ Test Results
8. Synthetic molecules hold promise for new family of anti-cancer drugs
9. Its Safe to Play on Desso Synthetic Turf
10. Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields
11. Oregon study raises questions on synthetic progestins
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: